Understanding patient views on labeling and reporting for low-grade prostate cancer
Official title: Patient Perspectives on Relabeling and Pathology Reporting for Grade Group 1 Prostate Cancer
Funded at University of California, San Francisco · NIH-11049000 · Data updated 2026-11-12
This study is looking to understand how people with low-grade prostate cancer feel about the word 'cancer' and how they prefer their pathology reports to be presented, so we can make sure everyone, including Spanish speakers, gets the information in a way that feels right for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2027 |
| Funding year | 2024 |
| Award (this year) | $350,000 |
| NIH project number | 1U48DP006853-01 |
| Project ID | NIH-11049000 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men diagnosed with Grade Group 1 prostate cancer, particularly from diverse backgrounds including Black and Hispanic populations.
✕Less likely to help
Patients with high-grade prostate cancer or those not diagnosed with prostate cancer may not benefit from this research.
What this research studies
This research investigates how patients perceive the term 'cancer' in relation to low-grade prostate cancer, which often has a slow progression. It aims to gather insights from diverse patient populations about their preferences for pathology report presentations. The study will involve qualitative interviews, discrete choice experiments, and a randomized trial to evaluate different wording in pathology reports. The research will be conducted in both English and Spanish to ensure inclusivity.
Why it matters
Potential benefit: If successful, this research could lead to more patient-friendly communication regarding low-grade prostate cancer, potentially reducing anxiety and improving patient understanding.
How similar studies have gone: While there is ongoing debate about cancer nomenclature, this specific approach to understanding patient perspectives is relatively novel and has not been extensively tested.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Ramirez-Valles, Jesus — University of California, San Francisco
- Study coordinator: Ramirez-Valles, Jesus
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.